Spectrum dropped over 9%, after it was revealed that the Company had failed to disclose that the FDA had advised it to not submit a New Drug Application for its drug candidate apaziquone back in December of 2012. Only later did Spectrum tell its investors that "we took this data, met with the FDA, and our understanding is and our decision is that we can go ahead and file the NDA with this drug." One journalist wrote, that "was not a fully truthful summary of the FDA's guidance to Spectrum."
If you are aware of any facts relating to this investigation, or purchased shares of Spectrum, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/sppi. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-spectrum-pharmaceuticals-inc-sppi-300329955.html
SOURCE Bronstein, Gewirtz & Grossman, LLC